Potential Reduction in Adverse Events and Cost with Novel Anticoagulants among Patients with Acute Limb Ischemia
Table 1
Baseline covariates of veterans in the ALI cohort and patients with PAD in the COMPASS trial.
ALI cohort
COMPASS PAD cohort
value
n
286
2492
Age
66.9 (8.7)
67.9 (8.45)
0.06
Male
274 (95.8%)
1774 (71%)
<0.001
BMI
26.7 (5.4)
28.3 (5.0)
<0.001
Systolic BP
135.2 (13.6)
138.9 (18.5)
<0.001
Diastolic BP
76.1 (8.3)
77.7 (10.1)
0.003
Current or former smoker
160 (55.9%)
1829 (73.4%)
<0.001
Median cholesterol (mmol/L)
4.3 (3.5-5)
4.2 (3.6-5.0)
N/A
Hypertension
255 (89.2%)
1966 (78.9%)
<0.001
Diabetes
119 (41.6%)
1100 (44.1%)
0.45
History of stroke
31 (10.8%)
171 (6.9%)
0.02
mL/min
74 (32.5%)
688 (27.6%)
0.138
Medications
Antiplatelets
242 (84.6%)
2185 (87.7%)
0.166
Statin
224 (78.3%)
2088 (83.8%)
0.024
ACE-I or ARB
165 (57.7%)
1715 (68.8%)
<0.001
Beta blocker
181 (63.3%)
1477 (59.3%)
0.212
Proton pump inhibitor
146 (51%)
826 (33.1%)
<0.001
Primary treatment strategy
Revascularization
168 (59%)
—
—
Endovascular
121 (42%)
—
—
Surgical
63 (22%)
—
—
Amputation
14 (5%)
—
—
None
115 (40%)
—
—
(i) Data presented as mean (standard deviation) for continuous variables or proportions for categorical variables. (ii) Abbreviations: Std Diff: absolute standardized difference. (iii) Because the full data from the PAD subgroup analysis were unavailable, we could not formally test the difference in medians between the ALI veteran cohort and the COMPASS trial PAD subgroup.
